DNSP-11
Also known as: Dopamine Neuron Stimulating Peptide-11
GDNF-Derived Peptide | Dopaminergic Neuroprotection
Overview
DNSP-11 is an 11-amino acid peptide derived from the pro-domain of glial cell line-derived neurotrophic factor (GDNF). It was designed to capture the neuroprotective properties of GDNF while avoiding the limitations of the full-length protein, including poor blood-brain barrier penetration, off-target effects, and manufacturing complexity. Preclinical research demonstrates that DNSP-11 protects and stimulates dopaminergic neurons, making it a compound of significant interest for Parkinson's disease research and biohacking communities focused on dopamine system health.
Key benefits
- Protects dopaminergic neurons from neurotoxic insults
- Stimulates dopamine production via tyrosine hydroxylase upregulation
- Smaller molecule with improved bioavailability compared to full GDNF
- Does not require GFRalpha1/RET receptor complex for activity
- Preclinical evidence for neuroprotection in Parkinson's disease models
- Compatible with intranasal and subcutaneous administration
Mechanism of action
DNSP-11 acts on dopaminergic neurons through mechanisms distinct from full-length GDNF. Rather than binding to the canonical GFRalpha1/RET receptor complex, DNSP-11 appears to engage alternative signaling pathways to promote dopaminergic neuron survival, stimulate dopamine release, and protect against neurotoxin-induced damage. It enhances tyrosine hydroxylase expression (the rate-limiting enzyme in dopamine synthesis) and supports mitochondrial function in dopaminergic neurons.
Molecular data
- Type
- GDNF pro-domain derived peptide
- Half-life
- Not well characterized
Sequence
Pro-Pro-Glu-Ala-Pro-Ala-Glu-Asp-Arg-Ser-Leu
Indications
What the research community uses this compound for, with self-reported effectiveness.
Neuroprotection
Cognitive
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 100-200mcg | 1x daily | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 100-200mcg | 1x daily | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Nasal irritation or mild burning sensation (intranasal route)
- Injection site reactions such as redness or swelling (subcutaneous route)
Contraindications
- Pregnancy or breastfeeding
- Known peptide allergies
- Very limited human safety data; use at own risk
- Consult a physician before combining with dopaminergic medications
Monitoring
- Start with the lowest dose (100mcg) to assess individual response
- Monitor for changes in mood, sleep, or motivation
- Track injection site or nasal reactions
- Avoid combining with high-dose dopaminergic drugs without medical supervision
References
Primary literature and clinical-trial data informing this entry.